Subscribe To
KZIA / Kazia Therapeutics appoints US-based CFO to assist global market expansion
KZIA News
By PRNewsWire
September 8, 2022
KAZIA TO PRESENT FINAL DATA FROM PAXALISIB PHASE II STUDY IN GLIOBLASTOMA AT ESMO
SYDNEY , Sept. 8, 2022 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, today announ more_horizontal
By Proactive Investors
December 12, 2021
Kazia Therapeutics appoints US-based CFO to assist global market expansion
Kazia Therapeutics Ltd (ASX:KZA, NASDAQ:KZIA) has appointed Karen Krumeich as chief financial officer to focus on building and maintaining relationsh more_horizontal
By Proactive Investors
December 12, 2021
Kazia Therapeutics appoints US-based CFO to assist global market expansion
Kazia Therapeutics Ltd (ASX:KZA, NASDAQ:KZIA) has appointed Karen Krumeich as chief financial officer to focus on building and maintaining relationsh more_horizontal
By Proactive Investors
December 12, 2021
Kazia Therapeutics appoints US-based CFO to assist global market expansion
Kazia Therapeutics Ltd (ASX:KZA, NASDAQ:KZIA) has appointed Karen Krumeich as chief financial officer to focus on building and maintaining relationsh more_horizontal
By Proactive Investors
November 28, 2021
Kazia Therapeutics expands further in North America with Toronto glioblastoma study
Kazia Therapeutics Ltd (ASX:KZA, NASDAQ:KZIA)'s cancer drug, paxalisib, which targets glioblastoma, will now reach patients in Canada through a new more_horizontal
By Proactive Investors
November 28, 2021
Kazia Therapeutics expands further in North America with Toronto glioblastoma study
Kazia Therapeutics Ltd (ASX:KZA, NASDAQ:KZIA)'s cancer drug, paxalisib, which targets glioblastoma, will now reach patients in Canada through a new more_horizontal
By Proactive Investors
November 28, 2021
Kazia Therapeutics expands further in North America with Toronto glioblastoma study
Kazia Therapeutics Ltd (ASX:KZA, NASDAQ:KZIA)'s cancer drug, paxalisib, which targets glioblastoma, will now reach patients in Canada through a new more_horizontal
By Proactive Investors
November 14, 2021
Kazia Therapeutics appoints former Cellectar Biosciences chief medical officer John Friend as new CMO
Kazia Therapeutics Ltd (ASX:KZA, NASDAQ:KZIA) has appointed John Friend MD, the former chief medical officer (CMO) at Cellectar Biosciences (NASDAQ:CL more_horizontal